Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) EBITDA Margin: 2020-2023

Historic EBITDA Margin for Candel Therapeutics (CADL) over the last 4 years, with Dec 2023 value amounting to -228.43%.

  • Candel Therapeutics' EBITDA Margin rose 2590383.00% to -228.43% in Q4 2023 from the same period last year, while for Dec 2023 it was -1,479.42%, marking a year-over-year increase of 2652138.00%. This contributed to the annual value of -1,596.70% for FY2024, which is 11728.00% down from last year.
  • According to the latest figures from Q4 2023, Candel Therapeutics' EBITDA Margin is -228.43%, which was down 117.25% from 1,324.51% recorded in Q3 2023.
  • In the past 5 years, Candel Therapeutics' EBITDA Margin ranged from a high of 5,148.39% in Q4 2021 and a low of -52,135.48% during Q3 2021.
  • In the last 3 years, Candel Therapeutics' EBITDA Margin had a median value of -14,733.87% in 2021 and averaged -15,357.73%.
  • Data for Candel Therapeutics' EBITDA Margin shows a peak YoY increase of 3,910,968bps (in 2021) and a maximum YoY decrease of 4,388,387bps (in 2021) over the last 5 years.
  • Over the past 4 years, Candel Therapeutics' EBITDA Margin (Quarterly) stood at -33,961.29% in 2020, then surged by 3,910,968bps to 5,148.39% in 2021, then crashed by 3,128,065bps to -26,132.26% in 2022, then spiked by 2,590,383bps to -228.43% in 2023.
  • Its EBITDA Margin was -228.43% in Q4 2023, compared to 1,324.51% in Q3 2023 and 1,487.42% in Q2 2023.